Today’s Top Three in Pharma 012209

Social Networking in our industry*. PharmaExec looks at the use of social networking platforms among physicians. And, an abstract of Manhattan Research‘s findings (scroll past TOC to read excerpt). A new kind of social network has been gaining traction among doctors – namely, physician-only communities where doctors can exchange ideas, opinions, and information about treatments with their peers…

Earnings reports: Abbott Labs comes in strong. J&J, maybe not so much. King, looking at increasing threats from generics.

Obesity may be a top health concern, but the drugs developed to treat it aren’t getting rave reviews.

* As a long-time user of social media applications, I have a deep interesting in the use of these approaches in pharma. The challenges of social media use in a highly-regulated industry are well-documented and problematic. But it won’t be an option in the future. Every pharma will have to deal with the FACT that social media use is increasingly pervasive, and responsible PR/Communications/Marketing must come to grips with it.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.